Citigroup Cuts GoodRx (NASDAQ:GDRX) Price Target to $6.25

GoodRx (NASDAQ:GDRX) had its price objective reduced by Citigroup from $7.00 to $6.25 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

GDRX has been the topic of several other research reports. Barclays dropped their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Morgan Stanley dropped their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. KeyCorp lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Finally, Mizuho assumed coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective for the company. Five analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $8.38.

GoodRx Stock Up 6.3 %

Shares of NASDAQ:GDRX opened at $4.55 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The stock has a market cap of $1.73 billion, a P/E ratio of -151.67, a P/E/G ratio of 3.43 and a beta of 1.27. GoodRx has a 1-year low of $4.09 and a 1-year high of $9.26. The firm has a fifty day moving average price of $4.72 and a 200 day moving average price of $6.55.

Institutional Investors Weigh In On GoodRx

Large investors have recently added to or reduced their stakes in the business. American Century Companies Inc. purchased a new stake in GoodRx during the 2nd quarter worth about $18,183,000. Point72 Asset Management L.P. acquired a new stake in shares of GoodRx during the 3rd quarter worth about $11,295,000. Rubric Capital Management LP grew its holdings in shares of GoodRx by 76.5% during the second quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock worth $29,147,000 after buying an additional 1,619,748 shares in the last quarter. Millennium Management LLC raised its position in shares of GoodRx by 36.5% in the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock valued at $32,151,000 after buying an additional 1,102,758 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new position in shares of GoodRx during the third quarter valued at approximately $5,675,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.